Core Viewpoint - The China Securities Regulatory Commission (CSRC) has imposed penalties on Jincheng Pharmaceutical's actual controller Zhao Yeqing for leading a stock manipulation case lasting two and a half years, resulting in his resignation as chairman [3][10][25]. Group 1: Stock Manipulation Case - Zhao Yeqing was fined 1.5 million yuan and banned from the market for four years due to stock manipulation activities [3][10]. - The manipulation involved 104 securities accounts, with over 4 billion yuan in fund transactions, and the accounts participated in trading for 502 out of 595 trading days [6][32]. - Despite the extensive manipulation, the account group incurred a loss of approximately 7.39 million yuan during the operation [7][34]. Group 2: Company Operations and Financials - Jincheng Pharmaceutical, established in 2004 and listed in 2011, specializes in the research, production, and sales of pharmaceutical intermediates and raw materials [15][39]. - The company reported a revenue of 3.373 billion yuan in 2024, a decrease of 4.66% year-on-year, with significant fluctuations in net profit [22][46]. - Recent financial data shows a decline in revenue and net profit, with Q3 2023 revenue at 572 million yuan, down 24.44% year-on-year, and a net loss of 11.81 million yuan [24][48]. Group 3: Management Changes and Future Outlook - Following the penalties, the company emphasized that the operational management would not be affected and plans to elect a new chairman soon [10][25]. - The market is closely watching how the management will adjust in light of the recent events and the ongoing operational pressures [35][49].

（文章来源：证券日报） 证券日报网讯 12月12日，金城医药在互动平台回答投资者提问时表示，目前公司经营情况正常。公司 深耕"医药化工、合成生物学、女性健康科技、高端抗感染、新型烟草"领域，形成了以五大领域为战略 支撑的整体发展布局。公司凭借着稳定优质的产品质量，在行业内拥有较好的口碑，像AE活性酯、头 孢他啶活性酯、谷胱甘肽原料药等，此外公司抗生素注射剂、口服剂以及妇科口服、外用制剂等产品也 以优秀的品质在各自的治疗领域发挥着重要作用。2025年，公司多项产品完成国内国际注册，产品更加 丰富，竞争力进一步提升。公司将不断加大市场开拓力度，积极拓展新客户、新市场，持续推动公司发 展和经营业绩的提升。 ...

中国经济网北京12月12日讯 金城医药(300233.SZ)今日发布关于公司实际控制人收到行政处罚决定书的公 告。2025年12月10日，公司收到实际控制人赵叶青的通知，其收到中国证监会《行政处罚决定书》（处罚字 ﹝2025﹞147号），主要内容如下： 经查明，当事人存在以下违法事实：2017年8月18日至2020年2月10日(以下简称操纵期间)，赵叶青、王 震、刘峰3人共同操纵"金城医药"股票。其中，赵叶青是操纵行为的决策者，王震是操纵行为的主要实施者，刘 峰是操纵行为的次要实施者。 一、控制使用证券账户情况 根据当事人自认、他人指认、证券账户开户资料及情况说明、证券及银行账户资金往来记录、证券账户交 易流水等证据，操纵期间赵叶青、王震、刘峰控制使用相关账户组共104个账户交易"金城医药"股票。 经测算，账户组实际亏损7,392,044.45元。 赵叶青、王震、刘峰的上述行为违反2005年《证券法》第七十七条第一款第一项、第三项的规定，构成 2005年《证券法》第二百零三条所述操纵证券市场的违法行为。根据当事人违法行为的事实、性质、情节与社 会危害程度，中国证监会决定: 一、依据2005年《证券法》第二百零 ...

根据金城医药相关公告显示，公司已收到董事长赵叶青提交的书面辞职报告，其因个人原因辞去公司董 事长、董事及董事会下设专门委员会相关职务。赵叶青的辞职自辞职报告送达董事会时生效，辞职生效 后，赵叶青将不再担任公司任何职务。 根据当事人自认、他人指认、证券账户开户资料及情况说明、证券及银行账户资金往来记录、证券账户 交易流水等证据，操纵期间赵叶青、王震、刘峰控制使用相关账户组共 104 个账户交易"金城医药"股 票。 近日，金城医药（300233）发布公告称，公司收到实际控制人赵叶青的通知，其收到中国证监会《行政 处罚决定书》，处罚书内容主要内容包括，依据 2005 年修订的《中华人民共和国证券法的有关规定， 证监会对赵叶青、王震、刘峰操纵山东金城医药集团股份有限公司股票行为进行了立案调查，本案现已 调查、办理终结。 根据当事人违法行为的事实、性质、情节与社会危害程度，证监会会决定:一、依据 2005 年《证券法》 第二百零三条的规定，对赵叶青、王震、刘峰处以 300 万元罚款，其中赵叶青承担 150 万元，王震承担 120 万元，刘峰承担30 万元。 依据 2005 年《证券法》第二百三十三条和《证券市场禁入规定 ...

Core Viewpoint - The chairman of Jincheng Pharmaceutical, Zhao Yeqing, has resigned following a formal penalty from the China Securities Regulatory Commission (CSRC) for stock manipulation, which included a fine of 1.5 million yuan and a four-year market ban [1][6]. Summary by Sections Announcement of Resignation and Penalty - Zhao Yeqing submitted his resignation as chairman and other board positions due to personal reasons, coinciding with the issuance of the CSRC's administrative penalty decision [1][7]. - The penalty includes a fine of 1.5 million yuan for Zhao Yeqing, with additional fines for co-conspirators Wang Zhen and Liu Feng, totaling 3 million yuan [6]. Details of Stock Manipulation - From August 18, 2017, to February 10, 2020, Zhao Yeqing, along with Wang Zhen and Liu Feng, manipulated Jincheng Pharmaceutical's stock using 104 accounts over nearly 600 trading days, resulting in a loss of approximately 7.39 million yuan [2][4]. - The account group held an average of 18.58 million shares, representing 5.68% of the company's circulating shares, with a peak holding of 32.09 million shares, or 9.04% [4]. Impact on Stock Price - During the manipulation period, the account group exhibited significant buying interest, accounting for 17.29% of the market's buy orders and 23.02% of the market's trading volume at certain times, leading to a stock price increase of 21.30% compared to a 2.90% increase in the ChiNext index [4][5]. Evidence and Regulatory Findings - The CSRC found sufficient evidence of coordinated manipulation, including transaction records and witness testimonies, and rejected the defendants' claims of lack of intent and other defenses [6][9]. - The investigation and hearing process lasted over a year, with the CSRC's decision marking the conclusion of the investigation into Zhao Yeqing's actions [9].

拉扯半年多收最终处罚决定 金城医药实控人带着另外两人横跨两年半，大举操纵自家股票，但非但没有挣到钱还倒亏了大几百万， 最终还被证监会处以罚款，罚款金额倒是不大，但是还吃到了一个四年市场禁入的处罚，把董事长的职 务也给丢了。 来源：飞瞰财金 12月11日晚间，金城医药（维权）公告了一份颇有戏剧性的行政处罚。 时间回溯到一年多前的2024年8月15日，金城医药公告，公司实际控制人、董事长赵叶青收到中国证监 会下发的《立案告知书》（编号：证监立案字0392024015号）。因涉嫌操纵证券市场违法违规行为，根 据《证券法》《行政处罚法》等法律法规，证监会决定对赵叶青立案。 2025年3月12日，赵叶青首次收到中国证监会的《行政处罚事先告知书》，此次赵叶青、王震、刘峰被 并处以4631.74万元的巨额罚款，其中赵叶青承担2315.87万元，同时证监会对赵叶青采取4年市场禁入措 施，对王震采取3年市场禁入措施。不过，针对前述拟处罚决定，赵叶青不认可，向中国证监会申请进 行陈述、申辩和要求听证。 又经过半年多的拉扯，2025年9月30日，赵叶青收到中国证监会重新下发的《行政处罚事先告知书》， 并在2025年12月10日收到 ...

Group 1 - Lu Kang Pharmaceutical plans to increase capital by 109 million yuan to its wholly-owned subsidiary Bio-Pesticide Company and 27 million yuan to Ze Run Company, aiming to expand its pesticide and sales sectors [1] - Hui Green Ecology intends to sell two properties in Ningbo for 12.52 million yuan, expecting a net profit impact of approximately 6.23 million yuan from the transaction [2] - Tianyuan Co., Ltd. plans to invest 185 million yuan in an intelligent upgrade project for its titanium dioxide production facilities [3] Group 2 - Metro Design has received approval from the Shenzhen Stock Exchange for its share issuance to acquire 100% equity of Guangzhou Metro Engineering Consulting Co., Ltd. for 511 million yuan [4] - South Network Energy announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 0.07 yuan per 10 shares [5] - Qibin Group plans to establish two wholly-owned subsidiaries in Shenzhen with a registered capital of 100 million yuan each [6] Group 3 - All New Good received an administrative regulatory decision from the Shenzhen Securities Regulatory Bureau due to issues in financial accounting and information disclosure [7] - Luokai Co., Ltd. announced that its shareholders plan to reduce their holdings by up to 3% of the company's shares [8][9] - Jincheng Pharmaceutical's actual controller received an administrative penalty from the CSRC for stock manipulation, leading to the resignation of the chairman [10] Group 4 - Yicheng New Energy intends to acquire a 7.69% stake in Kaifeng Times for 10 million yuan, enhancing its strategic development [11] - Yujing Co., Ltd. signed a sales contract worth approximately 28.6 million USD with an overseas photovoltaic company [12] - Nuocheng Jianhua's TRK inhibitor, Zoltracitinib, has been approved for market entry in China [13] Group 5 - Nandu Power announced that its controlling shareholder is planning a change in control, leading to a temporary suspension of its stock [14] - Xinxing Casting plans to acquire 100% equity of China Resources Steel for 1.244 billion yuan to focus on special steel development [15] - Xinlitai is planning to issue H-shares and list on the Hong Kong Stock Exchange [16] Group 6 - Blue Fan Medical's subsidiary received approval for a new medical device, the coronary artery scoring balloon dilation catheter [18] - China Iron & Steel plans to establish a joint venture with several companies to provide new energy transportation solutions with a registered capital of 500 million yuan [19] - Jifeng Technology intends to sign a cooperation framework agreement with Dongtai Lianfei for a total transaction amount not exceeding 100 million yuan [20] Group 7 - Zhongwei Electronics announced a change in its actual controller, with stock resuming trading [21] - Weihong Co., Ltd. plans to reduce its holdings by up to 1.15% of the company's shares [22] - Te Fa Information received a criminal judgment related to a fraud case involving the acquisition of Shenzhen Te Fa Dongzhi Technology Co., Ltd. [23] Group 8 - Sunshine Dairy's controlling shareholder's concerted action plans to reduce holdings by up to 3% of the company's shares [24] - Meikailong reported that Taobao Holdings and New Retail Fund collectively reduced their H-shares by 30.616 million shares [25] - Xinjubang plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [26] Group 9 - Beite Technology's application for issuing A-shares to specific objects has been approved by the Shanghai Stock Exchange [28] - Victory Energy's controlling shareholder is planning a change in control, with stock resuming trading [29] - Jiutian Pharmaceutical signed a patent and technology transfer agreement for a small molecule analgesic drug project, with a total transfer fee not exceeding 400 million yuan [29]

据每日经济新闻报道，根据当事人自认、资金往来记录及交易流水等证据，赵叶青等人控制使用了包含 104个账户的账户组进行交易。经监管部门测算，该账户组在操纵期间累计竞价买入金额约21.34亿元， 卖出金额约18.70亿元，最终实际亏损739.20万元。面对监管层的调查，当事人关于"无操纵主观故意"的 申辩被悉数驳回。最终，赵叶青被处以150万元罚款及4年市场禁入措施，并辞去公司董事长职务。 12月11日晚间，金城医药(300233.SZ)发布两则公告：一份关于公司董事长赵叶青提交书面辞职，另一 份则关于他收到中国证监会《行政处罚决定书》。经查明，2017年8月18日至2020年2月10日期间，赵叶 青作为决策者，与王震（主要实施者）、刘峰（次要实施者）共同操纵了"金城医药"股票。 ...

智通财经记者 | 宋佳楠 12月11日，山东金城医药（维权）集团股份有限公司（300233.SZ）连发两则公告，揭开实控人带头操 纵股价案的终局：董事长赵叶青因主导长达近三年的股票操纵行为，被证监会罚款150万元并实施4年市 场禁入，当日其已正式辞去公司所有职务。 据证监会查明，2017年8月18日至2020年2月10日期间，赵叶青、王震、刘峰3人共同操纵金城医药股 票。其中，赵叶青是操纵行为的决策者，王震是操纵行为的主要实施者，刘峰是操纵行为的次要实施 者。根据当事人自认、他人指认、证券账户开户资料及情况说明、证券及银行账户资金往来记录、证券 账户交易流水等证据，操纵期间赵叶青、王震、刘峰控制使用相关账户组共104个账户交易金城医药股 票。 赵叶青、王震、刘峰三人通过集中资金优势、持股优势连续买卖，在自己实际控制的账户之间进行交易 等手段影响金城医药股票交易价格和交易量。 具体情况是，操纵期间共595个交易日，账户组在502天参与交易，累计竞价买入119，499，894股，金 额2，134，086，175.24元，累计竞价卖出107，162，145股，金额1，869，841，550.08元。账户组期初 持有 ...

白银价格持续高位震荡 12月11日，美国纽约商品交易所白银期货价格在首次突破每盎司60美元关口之后再次突破每盎司62美 元。国内市场方面，截至12月11日15：00收盘，上海期货交易所沪银主力合约报收于14488元/千克，也 继续上涨。东方金诚研究发展部副总监瞿瑞表示，白银价格短期将高位震荡。"一方面，美联储12月议 息会议如期降息25个基点符合市场预期，可能出现'预期兑现'引发的获利了结压力，同时白银现货紧 张，推升银价涨幅显著大于黄金，也会导致白银面临调整压力；另一方面，在光伏与新能源需求驱动 下，白银供给已连续5年小于需求，同时矿产白银产量增长有限、全球白银库存处于历史低位，供需缺 口持续扩大利好银价。"中长期来看，支撑白银上涨的核心逻辑未发生变化。国信期货研究所首席分析 师顾冯达分析称，随着新能源、电子制造等产业的快速发展，白银的工业应用场景持续拓宽，加剧市场 对白银供需缺口的担忧，吸引资金基于中长期逻辑进行布局。（经济参考报） 年内商业银行"二永债"发行规模达1.66万亿元 中国货币网信息显示，近日，上海银行完成发行年内首只无固定期限资本债券，发行规模为100亿元。 今年以来，商业银行持续通过发行二 ...